Advaxis has a broad pipeline maximizing the potential of Lm Technology™ in three separate areas of focus:
CLINICAL STAGE ASSETS
Five investigational immunotherapies targeting a range of types of cancers.
Advaxis’ lead Lm Technology™ immunotherapy axalimogene filolisbac targets HPV-associated cancers and is in clinical trials for two potential indications.
ADXS-PSA is under investigation for targeting the prostate-specific antigen (PSA) associated with prostate cancer and is in clinical development both as a monotherapy and in combination with immune checkpoint inhibitors for the treatments of metastatic castration-resistant prostate cancer (mCRPC).
Advaxis has licensed ADXS-HER2 to OS Therapies for the development in osteosarcoma in humans. HER2 is expressed in certain solid-tumor cancers, including some breast, gastric, and esophageal cancers and osteosarcoma.
Advaxis has embraced strategic collaborations with other major biopharmaceutical companies for the development and commercialization of some of its proprietary cancer immunotherapies. In addition, Advaxis is developing numerous distinct proprietary immunotherapies directly or in partnership with recognized cancer centers of excellence and with support from advocacy foundations.
Taking advantage of recent advances in genome sequencing with the capacity to target cancer neoantigens, Advaxis’ has two approaches for targeting neoantigens neoepitopes:
ADXS-NEO (in partnership with Amgen)